Delaware
|
001-37763
|
20-0709285
|
(State or other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
5201 Interchange Way, Louisville, KY
|
40229
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value
|
TPB
|
New York Stock Exchange
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02. |
Results of Operations and Financial Condition.
|
Item 7.01. |
Regulation FD Disclosure.
|
Item 9.01. |
Financial Statements and Exhibits.
|
(d)
|
Exhibits
|
|
99.1 | Press Release dated May 3, 2023 |
|
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
TURNING POINT BRANDS, INC.
|
|||
Dated: May 3, 2023
|
By:
|
/s/ Brittani N. Cushman
|
|
Brittani N. Cushman
|
|||
Senior Vice President, General Counsel and Secretary
|
|
• |
Total consolidated net sales increased 0.1% to $101.0 million
|
|
o |
Zig-Zag Products net sales decreased by 8.3% due to anticipated reduction of trade inventory during the quarter
|
|
o |
Stoker’s Products net sales increased by 6.2%
|
|
o |
Creative Distribution Solutions net sales increased by 8.0%
|
|
• |
Gross profit decreased 6.1% to $48.6 million
|
|
• |
Net income decreased 30.9% to $7.6 million
|
|
• |
Adjusted net income decreased 18.1% to $11.9 million (see Schedule B for a reconciliation to net income)
|
|
• |
Adjusted EBITDA decreased 17.7% to $20.8 million (see Schedule A for a reconciliation to net income)
|
|
• |
Diluted EPS of $0.41 and Adjusted Diluted EPS of $0.62 compared to $0.55 and $0.71 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)
|
|
• |
$0.1 million of ERP / CRM duplicative system costs compared to $0.3 million of ERP / CRP scoping expenses in the previous year
|
|
• |
$0.7 million of stock options, restricted stock and incentive expense compared to $1.2 million in the year-ago period
|
|
• |
$0.2 million of FDA PMTA-related expenses compared to $1.1 million in the year-ago period
|
|
• |
$0.0 million of transaction expenses as compared to $0.4 million in the year-ago period
|
|
• |
$0.0 million of restructuring costs as compared to $1.3 million in the year-ago period
|
|
Three Months Ended March 31,
|
|||||||
|
2023
|
2022
|
||||||
|
||||||||
Net sales
|
$
|
100,956
|
$
|
100,894
|
||||
Cost of sales
|
52,339
|
49,100
|
||||||
Gross profit
|
48,617
|
51,794
|
||||||
Selling, general, and administrative expenses
|
30,775
|
32,565
|
||||||
Operating income
|
17,842
|
19,229
|
||||||
Interest expense, net
|
4,010
|
5,196
|
||||||
Investment loss (gain)
|
4,799
|
(78
|
)
|
|||||
Gain on extinguishment of debt
|
(777
|
)
|
-
|
|||||
Income before income taxes
|
9,810
|
14,111
|
||||||
Income tax expense
|
2,468
|
3,340
|
||||||
Consolidated net income
|
7,342
|
10,771
|
||||||
Net loss attributable to non-controlling interest
|
(255
|
)
|
(227
|
)
|
||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
7,597
|
$
|
10,998
|
||||
|
||||||||
Basic income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.43
|
$
|
0.60
|
||||
Diluted income per common share:
|
||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
0.41
|
$
|
0.55
|
||||
Weighted average common shares outstanding:
|
||||||||
Basic
|
17,531,414
|
18,257,695
|
||||||
Diluted
|
20,669,152
|
21,749,510
|
||||||
|
||||||||
Supplemental disclosures of statements of income information:
|
||||||||
Excise tax expense
|
$
|
5,024
|
$
|
5,709
|
||||
FDA fees
|
$
|
195
|
$
|
124
|
|
(unaudited)
|
|||||||
|
March 31,
|
December 31,
|
||||||
ASSETS
|
2023
|
2022
|
||||||
Current assets:
|
||||||||
Cash
|
$
|
104,801
|
$
|
106,403
|
||||
Accounts receivable, net of allowances of $101 in 2023 and $114 in 2022
|
8,584
|
8,377
|
||||||
Inventories
|
113,738
|
119,915
|
||||||
Other current assets
|
19,961
|
22,959
|
||||||
Total current assets
|
247,084
|
257,654
|
||||||
Property, plant, and equipment, net
|
24,364
|
22,788
|
||||||
Deferred income taxes
|
8,069
|
8,443
|
||||||
Right of use assets
|
11,722
|
12,465
|
||||||
Deferred financing costs, net
|
256
|
282
|
||||||
Goodwill
|
136,253
|
136,253
|
||||||
Other intangible assets, net
|
82,821
|
83,592
|
||||||
Master Settlement Agreement (MSA) escrow deposits
|
28,710
|
27,980
|
||||||
Other assets
|
20,647
|
22,649
|
||||||
Total assets
|
$
|
559,926
|
$
|
572,106
|
||||
|
||||||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
10,390
|
$
|
8,355
|
||||
Accrued liabilities
|
25,932
|
33,001
|
||||||
Other current liabilities
|
20
|
20
|
||||||
Total current liabilities
|
36,342
|
41,376
|
||||||
Notes payable and long-term debt
|
393,578
|
406,757
|
||||||
Lease liabilities
|
10,072
|
10,593
|
||||||
Total liabilities
|
439,992
|
458,726
|
||||||
|
||||||||
Commitments and contingencies
|
||||||||
|
||||||||
Stockholders' equity:
|
||||||||
Preferred stock; $0.01 par value; authorized shares 40,000,000; issued and outstanding shares
-0-
|
-
|
-
|
||||||
Common stock, voting, $0.01 par value; authorized shares, 190,000,000; 19,901,989 issued shares and 17,585,529
outstanding shares at March 31, 2023, and 19,801,623 issued shares and 17,485,163 outstanding shares at December 31, 2022
|
199
|
198
|
||||||
Common stock, nonvoting, $0.01 par value; authorized shares, 10,000,000; issued and outstanding shares -0-
|
-
|
-
|
||||||
Additional paid-in capital
|
113,477
|
113,242
|
||||||
Cost of repurchased common stock (2,316,460 shares at March 31, 2023 and December 31, 2022)
|
(78,093
|
)
|
(78,093
|
)
|
||||
Accumulated other comprehensive loss
|
(2,234
|
)
|
(2,393
|
)
|
||||
Accumulated earnings
|
85,133
|
78,691
|
||||||
Non-controlling interest
|
1,452
|
1,735
|
||||||
Total stockholders' equity
|
119,934
|
113,380
|
||||||
Total liabilities and stockholders' equity
|
$
|
559,926
|
$
|
572,106
|
|
Three Months Ended March 31,
|
|||||||
|
2023
|
2022
|
||||||
Cash flows from operating activities:
|
||||||||
Consolidated net income
|
$
|
7,342
|
$
|
10,771
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Gain on extinguishment of debt
|
(777
|
)
|
-
|
|||||
Loss (gain) on sale of property, plant, and equipment
|
(6
|
)
|
1
|
|||||
Depreciation expense
|
776
|
871
|
||||||
Amortization of other intangible assets
|
771
|
463
|
||||||
Amortization of deferred financing costs
|
626
|
645
|
||||||
Deferred income tax expense (benefit)
|
299
|
(34
|
)
|
|||||
Stock compensation expense
|
743
|
1,159
|
||||||
Noncash lease income
|
(14
|
)
|
(5
|
)
|
||||
Loss (gain) on investments
|
4,897
|
(14
|
)
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(216
|
)
|
(2,958
|
)
|
||||
Inventories
|
6,173
|
(18,258
|
)
|
|||||
Other current assets
|
2,639
|
1,081
|
||||||
Other assets
|
(2,895
|
)
|
382
|
|||||
Accounts payable
|
2,051
|
22,101
|
||||||
Accrued liabilities and other
|
(7,025
|
)
|
(3,165
|
)
|
||||
Net cash provided by operating activities
|
$
|
15,384
|
$
|
13,040
|
||||
|
||||||||
Cash flows from investing activities:
|
||||||||
Capital expenditures
|
$
|
(2,435
|
)
|
$
|
(2,787
|
)
|
||
Restricted cash, MSA escrow deposits
|
-
|
(8,468
|
)
|
|||||
Proceeds on the sale of property, plant and equipment
|
3
|
1
|
||||||
Net cash used in investing activities
|
$
|
(2,432
|
)
|
$
|
(11,254
|
)
|
||
|
||||||||
Cash flows from financing activities:
|
||||||||
Repurchased Convertible Senior Notes
|
$
|
(13,002
|
)
|
$
|
-
|
|||
Proceeds from call options
|
33
|
-
|
||||||
Payment of dividends
|
(1,052
|
)
|
(1,022
|
)
|
||||
Exercise of options
|
357
|
245
|
||||||
Redemption of performance restricted stock units
|
(889
|
)
|
(1,141
|
)
|
||||
Common stock repurchased
|
-
|
(10,622
|
)
|
|||||
Net cash used in financing activities
|
$
|
(14,553
|
)
|
$
|
(12,540
|
)
|
||
|
||||||||
Net decrease in cash
|
$
|
(1,601
|
)
|
$
|
(10,754
|
)
|
||
Effect of foreign currency translation on cash
|
$
|
(1
|
)
|
$
|
(3
|
)
|
||
|
||||||||
Cash, beginning of period:
|
||||||||
Unrestricted
|
106,403
|
128,320
|
||||||
Restricted
|
4,929
|
15,155
|
||||||
Total cash at beginning of period
|
111,332
|
143,475
|
||||||
|
||||||||
Cash, end of period:
|
||||||||
Unrestricted
|
104,801
|
126,045
|
||||||
Restricted
|
4,929
|
6,673
|
||||||
Total cash at end of period
|
$
|
109,730
|
$
|
132,718
|
Three Months Ended
March 31,
|
||||||||
2023
|
2022
|
|||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
7,597
|
$
|
10,998
|
||||
Add:
|
||||||||
Interest expense, net
|
4,010
|
5,196
|
||||||
Gain on extinguishment of debt
|
(777
|
)
|
-
|
|||||
Income tax expense
|
2,468
|
3,340
|
||||||
Depreciation expense
|
776
|
871
|
||||||
Amortization expense
|
771
|
463
|
||||||
EBITDA
|
$
|
14,845
|
$
|
20,868
|
||||
Components of Adjusted EBITDA
|
||||||||
Corporate restructuring (a)
|
-
|
1,332
|
||||||
ERP/CRM (b)
|
138
|
330
|
||||||
Stock options, restricted stock, and incentives expense (c)
|
743
|
1,159
|
||||||
Transactional expenses (d)
|
4
|
425
|
||||||
FDA PMTA (e)
|
158
|
1,139
|
||||||
Non-cash asset impairment (f)
|
4,897
|
-
|
||||||
Adjusted EBITDA
|
$
|
20,785
|
$
|
25,253
|
(a) |
Represents costs associated with corporate restructuring, including severance.
|
(b) |
Represents cost assosicated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses.
|
(c) |
Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units ("PRSUs").
|
(d) |
Represents the fees incurred for transaction expenses.
|
(e) |
Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA").
|
(f) |
Represents impairment of investment assets.
|
(dollars in thousands except share data)
|
||||||||||||||||
(unaudited)
|
Three Months Ended
|
Three Months Ended
|
||||||||||||||
March 31, 2023
|
March 31, 2022
|
|||||||||||||||
|
Net Income
|
Diluted EPS
|
Net Income
|
Diluted EPS
|
||||||||||||
GAAP EPS
|
$
|
7,597
|
$
|
0.41
|
$
|
10,998
|
$
|
0.55
|
||||||||
Gain on extinguishment of debt (a)
|
(582
|
)
|
(0.03
|
)
|
-
|
-
|
||||||||||
Corporate restructuring (b)
|
-
|
-
|
1,017
|
0.05
|
||||||||||||
ERP/CRM (c)
|
103
|
0.00
|
252
|
0.01
|
||||||||||||
Stock options, restricted stock, and incentives expense (d)
|
556
|
0.03
|
885
|
0.04
|
||||||||||||
Transactional expenses (e)
|
3
|
0.00
|
324
|
0.01
|
||||||||||||
FDA PMTA (f)
|
118
|
0.01
|
869
|
0.04
|
||||||||||||
Non-cash asset impairment (g)
|
3,665
|
0.18
|
-
|
-
|
||||||||||||
Tax (expense) benefit (h)
|
415
|
0.02
|
152
|
0.01
|
||||||||||||
Adjusted
|
$
|
11,876
|
$
|
0.62
|
$
|
14,497
|
$
|
0.71
|
Totals may not foot due to rounding
|
(a) |
Represents gain on extinguishment of debt tax effected at the quarterly tax rate.
|
(b) |
Represents costs associated with corporate restructuring, including severance, tax effected at the quarterly tax rate.
|
(c) |
Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at the quarterly tax rate.
|
(d) |
Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate.
|
(e) |
Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate.
|
(f) |
Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate.
|
(g) |
Represents impairment of investment assets tax effected at the quarterly tax rate.
|
(h) |
Represents adjustment from quarterly tax rate to annual projected tax rate of 23% in 2023 and 2022.
|
|
Consolidated
|
Zig-Zag Products
|
Stoker's Products
|
Creative Distribution Solutions
|
||||||||||||||||||||||||||||
|
1st Quarter
|
1st Quarter
|
1st Quarter
|
1st Quarter
|
1st Quarter
|
1st Quarter
|
1st Quarter
|
1st Quarter
|
||||||||||||||||||||||||
|
2023
|
2022
|
2023
|
2022
|
2023
|
2022
|
2023
|
2022
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Net sales
|
$
|
100,956
|
$
|
100,894
|
$
|
41,887
|
$
|
45,672
|
$
|
33,662
|
$
|
31,703
|
$
|
25,407
|
$
|
23,519
|
||||||||||||||||
|
||||||||||||||||||||||||||||||||
Gross profit
|
$
|
48,617
|
$
|
51,794
|
$
|
22,390
|
$
|
26,343
|
$
|
19,465
|
$
|
17,686
|
$
|
6,762
|
$
|
7,765
|
||||||||||||||||
|
||||||||||||||||||||||||||||||||
Operating income
|
$
|
17,842
|
$
|
19,229
|
$
|
13,641
|
$
|
18,737
|
$
|
14,563
|
$
|
13,506
|
$
|
261
|
$
|
678
|
||||||||||||||||
Adjustments:
|
||||||||||||||||||||||||||||||||
Corporate restructuring
|
-
|
1,332
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
Transactional expenses
|
4
|
425
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
FDA PMTA
|
158
|
1,139
|
-
|
-
|
-
|
-
|
-
|
-
|
||||||||||||||||||||||||
Adjusted operating income
|
$
|
18,004
|
$
|
22,125
|
$
|
13,641
|
$
|
18,737
|
$
|
14,563
|
$
|
13,506
|
$
|
261
|
$
|
678
|